Genomics, a new bough of biotechnology responsible for gene mapping has acquired a rapid significance in the field of patents. Brisk growth of patent filing in genomic subject matter is raising serious concerns about their utility from the perspective of societal benefit. Though the genomic related patent application qualifies the criterion of invention and non-obviousness in major instances, the inventors are unable to satisfy the utility criterion. Some instances such as patent application for ESTs have no utility at all. The patent regulators constructed various tests to deal with the situation such as specificity, substantiality (real world) credibility tests etc. Hoverer, it is noteworthy that an attempt to uniform the standard of utility test for genomic inventions especially in the field of ESTs, cloning and creation of chimeras, has been made by America and Europe through specific regulations. Thus, the objective of this paper is firstly, to explain the importance of biotechnology and genomic inventions for mankind and significance of ESTs for future research. Secondly, to analyze the application of Utility code prior to the emergence of Utility code in America and Europe. Thirdly to scrutinize the Utility code in both countries and their implication on aftermath cases, and. fourthly and finally, to critically evaluate the both countries utility pathways in the light of societal benefit.
The science of genomics correlates genetic information with biochemical pathways and specifically with disease mechanisms (Grubb, 2010) . Genomics is an inspiring development of very large longitudinal cohort study and even study of entire populations to establish repositories of biological materials ("bio-banks") for discovery and characterization of genes associated with common diseases (Khoury et. al., 2004) . These "bio-banks" are an important advancement in the study of human genetics which will be identifying and characterizing numerous common genetic variants at specific loci, its combination sequence with other genes and the related chemical, physical, infectious, pharmacological and social factors. With the growth and consolidation of the biotechnology sector based upon genetic engineering that precipitated Intellectual Property into the protection of life forms and their structural and functional components. Art. 27(1) of Trade Related Aspects on Intellectual Property provides that patents shall be available and rights shall be enjoyable without discrimination as to the place of invention, the field of technology and to the place of production.
Thus, the judicial determination (e.g., Diamond V. Chankrabarty Case) in USA and legislation (e.g., Directive 98/44 of the EU Parliament and of the European Council, July 6, 1998 on the Legal Protection of Biotechnological Inventions, (1998) O.J. L213/13-21) in Europe treated the modification of genetic material as inventions rather than discoveries, thereby created the possibility of patenting of genetic material and enabling technologies (Blakeney, 2009 ). However, the latest developments after the exploration of Human Genome Project (Dutfield, 2003) 
I. Refurbishment of utility code by Americans
Legally speaking, a person can get patent over his invention only if his invention is New/Novel, having Inventive
Step/Non-obviousness and having Industrial Application/Utility. In other words Invention that divide of these criteria can never qualify as patent. More over the modern biotechnology revolution has enabled the patent filing in genomic subject matter. However, the genomic related patent application qualifies the criterion of novelty and non-obviousness in major instances; but the inventors are unable to satisfy the utility criterion.
However, the conjoin reading of American Constitutional provision (Art I, § 8, Cl 8, empower congress 'to promote the progress of science and useful arts".) and the 35 USC § 101 of The Patent Code instituted that; certain developments that even do not lead to an industrial product may be patented in America (Chisum and Jacobs, 1992) . For example, large number of patents granted in methods of doing business, and patenting of research tools, such as expression sequence tags and single nucleotide polymorphisms (USPTO Utility Examination Guidelines Federal Register, 2001).
Hence, it is a noticeable point that American legal framework allows the patentability of purely experimental inventions that cannot be made or used in an industry, or that do not produce a socalled technical effect (Dutfield, 2003) .
American Supreme Court in a landmark judgment of Diamond Vs. Chakrabarty, 447 US. 303, 206 USPQ 193 (1980) held that the patentee has produced a new bacterium with markedly different characteristics from any found in nature and one having the potential for significant utility, hence a live, human-made microorganism is patentable subject matter. In Merk & Co. v. Olin Mathieson Chemical Corp 253 F.2d 156 (1958) the court allowed purified vitamin to be patented which had no utility by relying on Judge Moore's explanation in Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) , that word "new utility" involves an 'enlargement of the range of utility' as compared to nature. Further, it is interesting to note that in Brenner V. Manson, 383 U.S. 519, 148 USPQ 689 (1966) , the court interpreted the utility condition as an essential requirement of a patent and insists that the inventor should discover at least a substantial minimal utility for his invention. After the aforesaid judgments, a patent applicant was allowed to make an assertion of utility, which likewise should be specific, substantial, and credible (Revised Interim Utility Guidelines Training Materials).
A specific and substantial utility excludes socalled "throw-away" utilities, such as the use of a complex invention as a landfill, or the use of a transgenic mouse as snake food. In Nelson v Bowler 626 F. 2d 853, 856, 206 U.S.P.Q. 881, 883 (CCPA 1980) , the CCPA has interpreted "substantial utility" as "practical utility" which is a shorthand way of attributing 'real world' value to claimed subject matter. In other words, one who is skilled in the art can use a claimed discovery in a manner which provides some immediate benefit to the public"(See, Guidelines for Examination of Applications for Compliance with the Utility Requirement).
However, it is noteworthy that, the disclosure of only one utility is required, not all possible uses, and the issue of marketability does not play a role. Speculative uses in the patent application are permitted as long as one use is practical. The use of a polynucleotide simply as a probe or chromosome marker, without disclosure of a specific DNA target, would not be considered specific (Document SCP/9/5) Geneva: WIPO, 2003 In Enzo Biochem, Inc v Gen-Probe Inc296 F. 3d 1316; 63 U.S.P.Q. 2d 1609 (Fed. Cir. 2002 ("Enzo II"), the Court of Appeals for the Federal Circuit (herein after CAFC) had the opportunity to test the relevance of Guidelines issued by the USPTO concerning the written description requirement of 35 U.S.C. 112, first paragraph. The CAFC stated that it is not bound by the USPTO Guidelines but may be given judicial notice to the extent they do not conflict with the statute. It should be kept in mind that the new Utility Guidelines do not affect the afore-named provisions in 35 U.S.C. Also, they are not binding on the CAFC (Barton, 2002 Wattanasin, 93 F.3d 1559 , 1563 (Fed. Cir. 1996 , it was ruled that a patent may not be granted to an invention unless substantial or practical utility for the invention has been discovered and disclosed. It was also observed in In re Diedrich and In re Kirk, preceding Fujikawa"that the nebulous expressions 'biological activity' or 'biological properties' appearing in the specification convey no more explicit indication of the usefulness of the compounds and how to use them than did the equally obscure expression 'useful for technical and pharmaceutical purposes' unsuccessfully relied upon by the appellant in. Thus, in addition to providing a "substantial" utility, an asserted use must also show that that claimed invention can be used to provide a well-defined and particular benefit to the public. Accordingly, the claimed ESTs are, in words of the Supreme Court, mere "objects of use-testing," to wit, objects upon which scientific research could be performed with no assurance that anything useful will be discovered in the end (Raghunath Lalgudi Case).
The Brenner court already in 1996 stated that "the Congress is not intended to grant patent on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing, a different set of rules was meant to apply to the process which yielded the un-patentable product."
Thus, applying the same logic, it can be asserted that the claimed ESTs, which do not correlate to an underlying gene of known function, fail to meet the standard for utility intended by Congress.
II. Refurbishment of utility code by Europeans:
Under . If a function is well known to be essential for human health, then the identification of the substance having this function will immediately suggest a practical application in case of a disease or condition caused by a deficiency. In such cases, an adequate description will ensure in accordance with the requirements of Article 57 EPC that "the inventioncan be made or used in industry"(T
0870/04 (BDP1 Phosphatase/MAX-PLANCK) EPO
). The requirement is that the industrial application of a sequence or a partial sequence of a gene must be disclosed in the patent application would appear to stem from the concerns expressed about the many patent applications that were filed for gene elements of totally unknown biological function (See,Arts 54, 56, 57 of EPC). Even if the language of Article 57 EPC were interpreted as meaning that the "making" referred to had to be in industry, there was nothing to indicate that the word "industry" had a particular or narrow meaning. In the context of this broad nature of industry, the "could be made in industry" test was more than enough for any invention. However, it is significant to note here that this interpretation of Rule 23(b) and (e) EPC must be made in conformity with Article 164(2) EPC and further Rule 27(1) (f) EPC imposed an additional practical requirement beyond Art.57 EPC.
In Appetite suppressant EPO -T0144/83 case, it has been observed that the notion of "industry" has to be interpreted broadly to include all manufacturing, extracting and processing activities of enterprises that are carried out continuously, independently and for financial (commercial) 
gains (EPO -T 0870/04 (BDP1
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Phosphatase/MAX-PLANCK). The requirement of Article 57 EPC that the invention"can be made or used" in at least one field of industrial activity emphasizes that a "practical" application of the invention has to be disclosed. Merely because a substance could be produced in some ways does not necessarily mean that this requirement is fulfilled, unless there is also some profitable use for which the substance can be employed (Appetite suppressant Case at 301).
In
Europe Thus genomic inventions such as genes and gene fragments that meet the standard patentability criteria of novelty, inventiveness and industrial applicability in principle are patentable subjectmatter (Crespi, 1999) . The second paragraph of Art.3 of the Directive clarifies that "Biological material which is isolated from its natural environment or produced by means of a technical process may be the subject of an invention even if it previously occurred in nature". Article 5 of the Directive addresses more specifically the patenting of sequences or partial sequences of genes.
Finally, the third paragraph of Art.5 of the Directive expands the criterion of industrial applicability in comparison to Art.3 which mentions the general patentability criteria of novelty, inventiveness and industrial applicability. According to the third section of Art.5 a new and specific requirement is created for the patentability of a sequence or a partial sequence of a gene, namely the requirement of disclosure of the industrial application of the nucleotide sequence in the patent application. This requirement does not apply to sequences or partial sequences of proteins (Aerts, 2004) .
The provision of Art.5 (3) of the Directive is found in the same words in rule 23e (3) of the Implementing Regulations to the EPC. The provision of rule 23e(3) EPC distinguishes genomic inventions from other inventions, for which it is sufficient if the invention "can be made or used" is sufficient to fulfill the requirement of industrial applicability under the EPC. The other relevant legal background that had to be taken into account was the EU Directive 98/44/EC on the legal protection of biotechnological inventions and its adoption by the EPO. Recitals (22) to (25), (28) and (34) all emphasized and made clear that the legislative intention was not to change relevant basic law, inter alia the provisions on susceptibility to industrial application.
There was no basis in the law for requiring a function of a sequence to be "specific" or for having any form of concern about the "vagueness" of a sequence's function. The examining division adopted the position that what was not "specific" was vague and, ipso facto, not enough for patentability. This view ignored the law and went against basic common sense and fundamental fairness. In fact, functions upon which industrial activity could be supported were often general and not "specific" in the way the examining division meant (EPO -T 0898/05 (Hematopoietic receptor/ZYMOGENETICS, 2006). In EPO -T 1452/06 (Serine protease/BAYER) of 10.05.2007 , the question raised as to whether, in the absence of the experimental evidence, the application provides enough support for the assumption that it has industrial application to fulfill Art.57 requirement. It has been argued that, although no experimental evidence has been provided for serine protease activity of a polypeptide of sequence SEQ ID NO: 24, the structural identification of this polypeptide as being a member of a family of proteins with known industrial interest, namely the family of serine proteases and the subgroup of type II membrane serine proteases, provides enough support for industrial applicability. This indication must have "a sound and concrete technical basis", as a "speculative indication of possible objectives that might or might not be achievable by carrying out further research with the tool as described is not sufficient for fulfillment of the requirement of industrial applicability". Basing on the "immediate concrete benefit" test the appeal has been dismissed. Sciences [2011] UKSC 51, was the first case to be heard before the UK Courts in genomics which rejected the patent application on the grounds that it lacked industrial applicability basing on the European Board of Appeal in T 0018/09 where in Lord Neuberger who referred to as 'the essence of the Board's approach in relation to the requirements of Article 57 in relation to biological material' on nine points.
Eli Lilly v Human Genome
However, the decisionin, HGS v. Eli-Lilly gives us guidance on how to deal with applications that apparently lack industrial application, and therefore these principles should be taken into consideration when assessing an invention for industrial application. In T 0641/05 Pharmacia/ GPCR-like receptor, the EPO Technical Board of Appeal made a distinction between a case where a substance has been elucidated or is known in the art, and a case where a substance is identified and possibly characterized, but its function is not known: industrial application can generally be acknowledged for the former and not for the latter. A claimed invention must have such a sound and concrete technical basis that the skilled person can recognize that its contribution to the art could lead to practical exploitation in industry, i.e. to a concrete benefit, which is immediately derivable directly from the description, if it is not already obvious from the nature of the invention or from the background art. It is necessary to disclose in definite technical terms the purpose of the invention and how it can be used in industrial practice to solve a given technical problem, this being the actual concrete benefit or advantage of exploiting the invention."
In Zymogenetics/ Haematopoietic receptor (not reported) (T 0898/05) , the lack of any industrial application for one aspect of an invention can have implications for other aspects of that invention. For example, if the one aspect of the invention is a receptor, the absence of any industrial application for the receptor would mean that an agonist to the receptor would also not be capable of industrial application. Similarly, a method of identifying agonists to the receptor would not be industrial applicable. On the other hand, if the specification established, for example by in vivo or in vitro data, that the receptor had some relevance to e.g. the treatment of obesity, the receptor, agonists and method of identifying agonists would all be capable of industrial application. Whilst a crystalline form of a protein may be novel it must have a specific, substantial and credible industrial application. The EPO, USPTO and JPO issued their trilateral report on protein 3D structure and related claims at the end of 2002. The practice of the Intellectual Property Office in this area is largely consistent with the conclusions of this trilateral study.
The legislative competence of the above implication may be flaw since a rule in the Implementing Regulations to the EPC cannot take precedence over an Article of the EPC (See, Art.164 (2) EPC). According to European patent law patentability is governed both by an intergovernmental treaty (the EPC) and by Community Law i.e., the Biotechnology Directive. Although r.23e(3) of EPC cannot take precedence over Art.57 EPC still it does not constitute substantive law and is binding as to the result to be achieved upon the Member States according to Art.249 EC Treaty.
III. Winding Up
The history of science and technology is incomplete without reference to biotechnology and genomics, which refers to the mapping, sequencing and analysis of the full set of genes of different organisms or species. Genomics is a rapidly emerging area of research which in the future years will revolutionize the understanding of biology (Chawla, 2002) . As one might expect, the human genome has always been the most interesting for governments and foundations, as well as for companies seeking to identify commercial applications from genomics (Dutfield, 2003) . The excavation of secrets behind nature created ample commercial potential after human genome project. The increased number of patent applications in the field of ESTs raised concerns about the requirement of balance between commercial and societal interest.
The arguments against patenting of gene in Diamond vsChakrabarty, initiated the further swing of row when it came to ESTs patenting as road block for future research. Though the utility standard among the three basic patentability criterions was applied liberally in olden days, after Brenner vs Manson, it has been considered as an essential requirement and declaring at least one substantial minimal utility has been considered important. The later judgments of American and European courts show the bumpy application of utility code for genomic inventions until the utility code haven't emerged in both countries as a process of standardization. The raising concern of society on the grounds of ethics and morality is the root cause for the oscillated application of utility code for genomic inventions. In some instances, the description of utility for some inventions is in such way that the end product has no known use in the present day context (In re Kirk Case). The utility code of both countries though tried to put a hold on the strong wave of ESTs patenting with its stratagem imposition of need of proof of practical utility and credibility yet there is flow of patent applications for ESTs. The American Supreme Court in the recent judgment laid down that patent cannot be granted for inventions which are mere "objects of use-testing", which has no assurance of raising anything useful end product (In re Dane K. Fisher and Raghunath . Lalgudi case). In the same way, European courts are also restricting the patenting of ESTs by applying the rule of concrete benefit, which is immediately derivable directly from the description (Eli Lilly Case).
A claimed invention must have such a sound and concrete technical basis that the skilled person can recognize that its contribution to the art could lead to practical exploitation in industry, i.e. to a concrete benefit, which is immediately derivable directly from the description, if it is not already obvious from the nature of the invention or from the background art. It is necessary to disclose in definite technical terms the purpose of the invention and how it can be used in industrial practice to solve a given technical problem, this being the actual concrete benefit or advantage of exploiting the invention."
From this it is evident that the Dedicated Biotechnology Firms are striving hard to overcome the regulatory hurdles to commercialize their inventions in various invented trickled methods in the interest of minority society. The substantial part of the society is clearly diverging from the above approach and raising their concerns related to morality and ethics. The need for balance is at the threshold of the regulators on whose shoulders the welfare of the larger mass of the society is resting. The jurisprudence behind granting monopoly rights for inventions should be uphold with a caution test of societal benefit linked with a standardization of utility code for emerging genomic research.
